Very slim chance this has been priced in with at least 2 more announcements expected this quarter and can now add an update to the pillar strategy this quarter to the list.
Another pillar de-risked significantly as validated with modern data! Don't underestimate the effect of cardiotoxicity in current anthracycline therapies.
Equivalence would have been enough with standard of care side effects, but now it's proving up to be an alternative therapy to resistant cancer cell lines as well --> this is a big big competitive advantage. From what I understand there's no breast cancer subtype evading bisantrene.
Holding long as always
Ann: Compelling Preclinical Breast Cancer Results, page-48
-
- There are more pages in this discussion • 206 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.055(2.92%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| $1.89 | $1.96 | $1.85 | $333.0K | 174.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3105 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.95 | 7574 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |